Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07548164 · ClinicalTrials.gov registry record · Phase 3

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 3
Development phase
224
Enrollment target

NCT07548164: Recruiting Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT07548164 is a Phase 3 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 224 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07548164, a Phase 3 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 3
Development phase
224 participants
Enrollment target

Study Summary

In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).

Primary Outcome

The primary objective is to demonstrate that Irreversible Electroporation/IRE boost is non-inferior with respect to negative biopsy rate at 2 years compared to Radiation Therapy/RT boost. This is measured by the two-year biopsy negative rate for the control group and the intervention group.

Interventions

  • RADIATION Stereotactic Body Radiation Therapy
  • DEVICE NanoKnife System

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2026-04-16
Est. Completion 2029-04-16
Phase Phase 3
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT07548164 shows while recruiting

NCT07548164 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.

NCT07548164 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07548164 about?

NCT07548164 is a clinical study titled "Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer". In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard stereotactic body rad...

What is the current status of trial NCT07548164?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2026-04-16. Estimated completion is 2029-04-16.

What interventions are being tested in trial NCT07548164?

The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), NanoKnife System (DEVICE).

Who is sponsoring clinical trial NCT07548164?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07548164's enrollment target sits among peer trials

224 1317th of 2000 higher than 684 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

  • NCT04140344 · 224 participants · NA

    The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

  • NCT04915183 · 224 participants · Phase 2

    Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

  • NCT05519878 · 224 participants · NA

    Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07548164, the US trial registry maintained by the National Library of Medicine. NCT07548164 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.